Expert Systems Marks Milestone in Tivoxavir Marboxil Clinical Development, Potential Single-Dose Flu Treatment

ROCKVILLE, Md., Oct. 10, 2024 /PRNewswire/ -- Expert Systems, renowned for integrating human and artificial intelligence to expedite drug discovery, marks a significant achievement in the development of tivoxavir marboxil. This compound is a promising inhibitor targeting the influenza protein CAP-dependent endonuclease (CEN) and is designed to combat a wide array of flu viruses. Created by Traws Pharma, Inc. (NASDAQ: TRAW), tivoxavir marboxil (tivoxavir) has demonstrated positive Phase 1 safety and pharmacokinetic outcomes, indicating its potential as a single-dose treatment for influenza.

Expert Systems' sophisticated AI-enabled platform played a crucial role in mitigating risks and expediting tivoxavir's progression from initial discovery to clinical trials. Phase 1 outcomes revealed favorable tolerability and a pharmacokinetic profile supportive of tivoxavir's use as a one-time flu treatment, including for pandemic strains. The successful conclusion of this study suggests that tivoxavir could become a leading inhibitor for drug-resistant influenza and avian flu viruses. Phase 2a trials, planned for early 2025, aim to further assess tivoxavir's capacity to reduce the public health impact of flu-related hospitalizations and fatalities, particularly among older adults and those at high risk.

"Tivoxavir's positive Phase 1 results highlight the effectiveness of our AI-powered platform in speeding up the development of innovative therapies," said Bill Farley, Chief Business Officer at Expert Systems. "Our platform minimizes risks during the early stages of drug development, cutting down on time and costs while enabling data-driven decisions. We are enthusiastic about supporting Traws Pharma in bringing this novel flu treatment to market."

Expert Systems, Inc., is an advanced development platform incorporating a hybrid AI-based system that spans the entire range of preclinical drug discovery and early-stage development. Their services include target identification, virtual screening, non-clinical and clinical pharmacology, chemical liability assessment, and toxicology. By leveraging a mix of proprietary and public databases, Expert Systems uses specialized software tools to analyze the intellectual property landscape and craft a strategic drug intelligence approach. This approach is designed to de-risk candidate selection, enabling a swift transition from computational models to initial human trials. Expert Systems has played a key role in forming Seed and Series A companies and overseeing more than 30 research and development initiatives in collaboration with various financial investors and strategic partners across North America, Europe, and Australia.